Table of Content

1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Treatment Type
2.4. Snippet by Route of Administration
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising FDA Drug Approvals
3.1.1.2. Rising Prevalence of DMD
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Drug Costs for DMD Treatment
3.1.2.2. Side Effects and Safety Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Advancements in Treatment Options
3.1.3.2. XX
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. North America Regulatory and Reimbursement Landscape
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Pipeline Analysis
4.9. Epidemiology Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
5. Duchenne Muscular Dystrophy Treatment Market, By Treatment Type
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
5.1.2. Market Attractiveness Index, By Treatment Type
5.2. Exon-Skipping Therapies*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Amondys 45 (Casimersen)
5.2.4. Exondys 51 (Eteplirsen)
5.2.5. Vyondys 53 (Golodirsen)
5.2.6. Viltepso (Viltolarsen)
5.3. Gene Therapies
5.4. Corticosteroids
5.4.1. Agamree
5.4.2. Emflaza (Deflazacort)
5.5. Others
6. Duchenne Muscular Dystrophy Treatment Market, By Route of Administration
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
6.1.2. Market Attractiveness Index, By Route of Administration
6.2. Oral*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Intravenous
7. Competitive Landscape and Market Positioning
7.1. Competitive Overview and Key Market Players
7.2. Market Share Analysis and Positioning Matrix
7.3. Strategic Partnerships, Mergers & Acquisitions
7.4. Key Developments in Product Portfolios and Innovations
7.5. Company Benchmarking
8. Company Profiles
Key Market Players
8.1. Sarepta Therapeutics, Inc.*
8.1.1. Company Overview
8.1.2. Product Portfolio
8.1.2.1. Product Description
8.1.2.2. Product Key Performance Indicators (KPIs)
8.1.2.3. Historic and Forecasted Product Sales
8.1.2.4. Product Sales Volume
8.1.3. Financial Overview
8.1.3.1. Company Revenue
8.1.3.2. Geographical Revenue Shares
8.1.3.3. Revenue Forecasts
8.1.4. Key Developments
8.1.4.1. Mergers & Acquisitions
8.1.4.2. Key Product Development Activities
8.1.4.3. Regulatory Approvals, etc.
8.1.5. SWOT Analysis
8.2. ITF Therapeutics LLC
8.3. NS Pharma, Inc.
8.4. Catalyst Pharmaceuticals, Inc.
8.5. PTC Therapeutics (List is not exhaustive)
Key Emerging Players
8.6. F. Hoffmann-La Roche Ltd
8.7. Capricor Therapeutics, Inc.
8.8. REGENXBIO Inc.
8.9. Solid Biosciences Inc.
8.10. Wave Life Sciences
8.11. Genethon (List is not exhaustive)
9. Assumptions and Research Methodology
9.1. Data Collection Methods
9.2. Data Triangulation
9.3. Forecasting Techniques
9.4. Data Verification and Validation
10. Appendix
10.1. About Us and Services
10.2. Contact Us